{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T22:47:27Z","timestamp":1790722047749,"version":"4.1.0"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T00:00:00Z","timestamp":1732665600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100015330","name":"Max Kade Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002066","name":"GSK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002066","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Atrial fibrillation and flutter (AF) are common in patients with Type 2 diabetes and are associated with worse outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>Harmony Outcomes was a multi-centre, event-driven, double-blind, placebo-controlled trial comparing the effects of albiglutide, a glucagon-like peptide-1 receptor agonist, with placebo on a composite of major adverse cardiac events (MACEs; non-fatal myocardial infarction, non-fatal stroke, and cardiovascular death) in 9463 patients aged &amp;gt;40\u2005years with Type 2 diabetes and established cardiovascular disease. Herein, the cardiovascular effects of albiglutide in patients with and without AF, as well as the effects on AF events during follow-up, were analysed. Patients with a history of AF (8.9%) exhibited a higher event rate for the primary composite MACE endpoint during 1.6\u2005years of follow-up {12.7 vs. 6.3 events\/100 person-years, adjusted hazard ratio [aHR] 1.41 [95% confidence interval (CI) 1.14\u20131.74], P = 0.001}. Treatment with albiglutide reduced the occurrence of the primary endpoint irrespective of history of AF at baseline (history of AF: aHR 0.83 [0.58\u20131.19], no history of AF: aHR 0.77 [0.66\u20130.90]; Pinteraction = 0.71). During follow-up, 239 patients (2.5%) experienced an AF event. Overall, albiglutide was associated with numerically fewer AF events [108 vs. 131; hazard ratio 0.82 (0.63\u20131.06), P = 0.12], irrespective of baseline history of AF (Pinteraction = 0.92).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In patients with Type 2 diabetes, treatment with albiglutide, compared with placebo, reduced the risk of cardiovascular events irrespective of history of AF. Further, albiglutide treatment did not increase AF adverse events but was associated with a trend to a lower rate of AF events during follow-up without reaching statistical significance<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/eurjpc\/zwae379","type":"journal-article","created":{"date-parts":[[2024,11,18]],"date-time":"2024-11-18T15:27:04Z","timestamp":1731943624000},"page":"30-41","source":"Crossref","is-referenced-by-count":6,"title":["Albiglutide and atrial fibrillation in patients with Type 2 diabetes and established cardiovascular disease: insights from the Harmony Outcomes trial"],"prefix":"10.1093","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7792-2837","authenticated-orcid":false,"given":"Konstantin A","family":"Krychtiuk","sequence":"first","affiliation":[{"name":"Duke Clinical Research Institute , 300 W Morgan Street, Durham, NC 27701 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Marquis-Gravel","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute , 300 W Morgan Street, Durham, NC 27701 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon","family":"Murphy","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute , 300 W Morgan Street, Durham, NC 27701 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Chiswell","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute , 300 W Morgan Street, Durham, NC 27701 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer B","family":"Green","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute , 300 W Morgan Street, Durham, NC 27701 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1040-6229","authenticated-orcid":false,"given":"Lawrence A","family":"Leiter","sequence":"additional","affiliation":[{"name":"Li Ka Shing Knowledge Institute, St. Michael\u2019s Hospital, 38 Shuter St, University of Toronto , Toronto, ON M5B 1A6 ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2999-4961","authenticated-orcid":false,"given":"Renato D","family":"Lopes","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute , 300 W Morgan Street, Durham, NC 27701 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Del Prato","sequence":"additional","affiliation":[{"name":"Section on Diabetes, Department of Clinical and Experimental Medicine, University of Pisa , Via Roma 67, 56126 Pisa ,","place":["Italy"]},{"name":"Sant\u2019Anna School of Advanced Studies , Piazza Martiri della Libert\u00e0, 33, 56127 Pisa ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J V","family":"McMurray","sequence":"additional","affiliation":[{"name":"British Heart Foundation Glasgow Cardiovascular Research Centre, University of Glasgow , 126 University Pl, Glasgow G12 8TA ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian F","family":"Hernandez","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute , 300 W Morgan Street, Durham, NC 27701 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher B","family":"Granger","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute , 300 W Morgan Street, Durham, NC 27701 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,11,27]]},"reference":[{"key":"2026010607172386400_zwae379-B1","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/j.jacc.2019.07.020","article-title":"Atrial fibrillation and diabetes mellitus: JACC review topic of the week","volume":"74","author":"Wang","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2026010607172386400_zwae379-B2","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1161\/CIRCULATIONAHA.118.038868","article-title":"Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal outcomes in type 2 diabetes mellitus","volume":"139","author":"Zelniker","year":"2019","journal-title":"Circulation"},{"key":"2026010607172386400_zwae379-B3","doi-asserted-by":"crossref","first-page":"S158","DOI":"10.2337\/dc24-S009","article-title":"9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes-2024","volume":"47","author":"American Diabetes Association Professional Practice Committee","year":"2024","journal-title":"Diabetes Care"},{"key":"2026010607172386400_zwae379-B4","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1093\/eurheartj\/ehad192","article-title":"2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes","volume":"44","author":"Marx","year":"2023","journal-title":"Eur Heart J"},{"key":"2026010607172386400_zwae379-B5","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials","volume":"9","author":"Sattar","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026010607172386400_zwae379-B6","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/j.numecd.2020.03.013","article-title":"Major cardiovascular events, heart failure, and atrial fibrillation in patients treated with glucagon-like peptide-1 receptor agonists: an updated meta-analysis of randomized controlled trials","volume":"30","author":"Nreu","year":"2020","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"2026010607172386400_zwae379-B7","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/S2213-8587(15)00233-8","article-title":"Cardiovascular safety of albiglutide in the Harmony programme: a meta-analysis","volume":"3","author":"Fisher","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026010607172386400_zwae379-B8","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ahj.2018.03.030","article-title":"Harmony Outcomes: a randomized, double-blind, placebo-controlled trial of the effect of albiglutide on major cardiovascular events in patients with type 2 diabetes mellitus-rationale, design, and baseline characteristics","volume":"203","author":"Green","year":"2018","journal-title":"Am Heart J"},{"key":"2026010607172386400_zwae379-B9","doi-asserted-by":"crossref","first-page":"101390","DOI":"10.1016\/j.diabet.2022.101390","article-title":"Antidiabetic agents and risk of atrial fibrillation\/flutter: a comparative critical analysis with a focus on differences between SGLT2 inhibitors and GLP-1 receptor agonists","volume":"48","author":"Scheen","year":"2022","journal-title":"Diabetes Metab"},{"key":"2026010607172386400_zwae379-B10","doi-asserted-by":"crossref","first-page":"euae061","DOI":"10.1093\/europace\/euae061","article-title":"Central obesity as a potential causal risk factor for atrial fibrillation: evidence from Mendelian randomization study","volume":"26","author":"Deng","year":"2024","journal-title":"Europace"},{"key":"2026010607172386400_zwae379-B11","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/S0140-6736(18)32261-X","article-title":"Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial","volume":"392","author":"Hernandez","year":"2018","journal-title":"Lancet"},{"key":"2026010607172386400_zwae379-B12","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1056\/NEJM198204293061703","article-title":"Epidemiologic features of chronic atrial fibrillation: the Framingham study","volume":"306","author":"Kannel","year":"1982","journal-title":"N Engl J Med"},{"key":"2026010607172386400_zwae379-B13","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1136\/heartjnl-2011-300503","article-title":"Type 2 diabetes, glucose homeostasis and incident atrial fibrillation: the Atherosclerosis Risk in Communities study","volume":"98","author":"Huxley","year":"2012","journal-title":"Heart"},{"key":"2026010607172386400_zwae379-B14","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.2337\/dc09-0939","article-title":"Independent contribution of diabetes to increased prevalence and incidence of atrial fibrillation","volume":"32","author":"Nichols","year":"2009","journal-title":"Diabetes Care"},{"key":"2026010607172386400_zwae379-B15","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1161\/CIRCULATIONAHA.108.825380","article-title":"Prevention of atrial fibrillation: report from a national heart, lung, and blood institute workshop","volume":"119","author":"Benjamin","year":"2009","journal-title":"Circulation"},{"key":"2026010607172386400_zwae379-B16","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1016\/j.jacc.2017.07.755","article-title":"Care patterns and outcomes in atrial fibrillation patients with and without diabetes: ORBIT-AF registry","volume":"70","author":"Echouffo-Tcheugui","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"2026010607172386400_zwae379-B17","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"2026010607172386400_zwae379-B18","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"2026010607172386400_zwae379-B19","doi-asserted-by":"crossref","first-page":"102382","DOI":"10.1016\/j.dsx.2021.102382","article-title":"Cardiovascular and mortality outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a meta-analysis with the FREEDOM cardiovascular outcomes trial","volume":"16","author":"Lee","year":"2022","journal-title":"Diabetes Metab Syndr"},{"key":"2026010607172386400_zwae379-B20","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1093\/ehjcvp\/pvae006","article-title":"Effects of albiglutide on myocardial infarction and ischaemic heart disease outcomes in patients with type 2 diabetes and cardiovascular disease in the Harmony Outcomes trial","volume":"10","author":"Krychtiuk","year":"2024","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2026010607172386400_zwae379-B21","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1161\/CIRCULATIONAHA.122.061620","article-title":"Long-term evolocumab in patients with established atherosclerotic cardiovascular disease","volume":"146","author":"O'Donoghue","year":"2022","journal-title":"Circulation"},{"key":"2026010607172386400_zwae379-B22","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1111\/dom.14634","article-title":"Dulaglutide and incident atrial fibrillation or flutter in patients with type 2 diabetes: a post hoc analysis from the REWIND randomized trial","volume":"24","author":"Raubenheimer","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"2026010607172386400_zwae379-B23","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1507\/endocrj.EJ21-0129","article-title":"Comprehensive analysis of the safety of semaglutide in type 2 diabetes: a meta-analysis of the SUSTAIN and PIONEER trials","volume":"68","author":"Yin","year":"2021","journal-title":"Endocr J"},{"key":"2026010607172386400_zwae379-B24","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.amjcard.2022.03.042","article-title":"Meta-analysis assessing the effect of tirzepatide on the risk for atrial fibrillation in patients with type 2 diabetes mellitus","volume":"173","author":"Patoulias","year":"2022","journal-title":"Am J Cardiol"},{"key":"2026010607172386400_zwae379-B25","doi-asserted-by":"crossref","first-page":"2602","DOI":"10.1007\/s00125-021-05551-y","article-title":"Glucose-lowering drug use and new-onset atrial fibrillation in patients with diabetes mellitus","volume":"64","author":"Fauchier","year":"2021","journal-title":"Diabetologia"},{"key":"2026010607172386400_zwae379-B26","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s12933-022-01549-x","article-title":"The risk of incident atrial fibrillation in patients with type 2 diabetes treated with sodium glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, and dipeptidyl peptidase-4 inhibitors: a nationwide cohort study","volume":"21","author":"Chan","year":"2022","journal-title":"Cardiovasc Diabetol"},{"key":"2026010607172386400_zwae379-B27","doi-asserted-by":"crossref","first-page":"e3436","DOI":"10.1002\/dmrr.3436","article-title":"GLP-1 RA and atrial fibrillation in the cardiovascular outcome trials","volume":"37","author":"Hamedi","year":"2021","journal-title":"Diabetes Metab Res Rev"},{"key":"2026010607172386400_zwae379-B28","doi-asserted-by":"crossref","first-page":"e0265","DOI":"10.1097\/XCE.0000000000000265","article-title":"Can glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors help in mitigating the risk of atrial fibrillation in patients with diabetes?","volume":"11","author":"Thotamgari","year":"2022","journal-title":"Cardiovasc Endocrinol Metab"},{"key":"2026010607172386400_zwae379-B29","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1093\/eurjpc\/zwae249","article-title":"The association of haemoglobin A1c variability with adverse outcomes in patients with atrial fibrillation prescribed anticoagulants","volume":"31","author":"Huang","year":"2024","journal-title":"Eur J Prev Cardiol"},{"key":"2026010607172386400_zwae379-B30","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s40618-021-01687-1","article-title":"Cardiovascular risk reduction throughout GLP-1 receptor agonist and SGLT2 inhibitor modulation of epicardial fat","volume":"45","author":"Iacobellis","year":"2022","journal-title":"J Endocrinol Invest"},{"key":"2026010607172386400_zwae379-B31","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/oby.21718","article-title":"Liraglutide causes large and rapid epicardial fat reduction","volume":"25","author":"Iacobellis","year":"2017","journal-title":"Obesity (Silver Spring)"},{"key":"2026010607172386400_zwae379-B32","first-page":"8181474","article-title":"Ameliorative impact of liraglutide on chronic intermittent hypoxia-induced atrial remodeling","volume":"2022","author":"Wang","year":"2022","journal-title":"J Immunol Res"},{"key":"2026010607172386400_zwae379-B33","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.jacbts.2023.01.005","article-title":"Glucagon-like peptide-1 protects against atrial fibrillation and atrial remodeling in type 2 diabetic mice","volume":"8","author":"Bohne","year":"2023","journal-title":"JACC Basic Transl Sci"},{"key":"2026010607172386400_zwae379-B34","doi-asserted-by":"crossref","first-page":"1019120","DOI":"10.3389\/fcvm.2022.1019120","article-title":"A meta-analysis evaluating indirectly GLP-1 receptor agonists and arrhythmias in patients with type 2 diabetes and myocardial infarction","volume":"9","author":"Liu","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"2026010607172386400_zwae379-B35","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/1479-5876-11-84","article-title":"Cardioprotective effects of lixisenatide in rat myocardial ischemia-reperfusion injury studies","volume":"11","author":"Wohlfart","year":"2013","journal-title":"J Transl Med"},{"key":"2026010607172386400_zwae379-B36","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s12933-016-0490-6","article-title":"Differential effects of glucagon-like peptide-1 receptor agonists on heart rate","volume":"16","author":"Lorenz","year":"2017","journal-title":"Cardiovasc Diabetol"},{"key":"2026010607172386400_zwae379-B37","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1161\/CIRCULATIONAHA.119.044183","article-title":"Effect of dapagliflozin on atrial fibrillation in patients with type 2 diabetes mellitus: insights from the DECLARE-TIMI 58 trial","volume":"141","author":"Zelniker","year":"2020","journal-title":"Circulation"},{"key":"2026010607172386400_zwae379-B38","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1111\/dom.14772","article-title":"Canagliflozin and atrial fibrillation in type 2 diabetes mellitus: a secondary analysis from the CANVAS program and CREDENCE trial and meta-analysis","volume":"24","author":"Li","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"2026010607172386400_zwae379-B39","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1093\/eurjpc\/zwad356","article-title":"Sodium-glucose co-transporter-2 inhibitors for the prevention of atrial fibrillation: a systemic review and meta-analysis","volume":"31","author":"Zhang","year":"2024","journal-title":"Eur J Prev Cardiol"},{"key":"2026010607172386400_zwae379-B40","first-page":"140","article-title":"Thiazolidinediones are associated with a decreased risk of atrial fibrillation compared with other antidiabetic treatment: a nationwide cohort study","volume":"3","author":"Pallisgaard","year":"2017","journal-title":"Eur Heart J Cardiovasc Pharmacother"}],"container-title":["European Journal of Preventive Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurjpc\/advance-article-pdf\/doi\/10.1093\/eurjpc\/zwae379\/60950094\/zwae379.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjpc\/article-pdf\/33\/1\/30\/60950094\/zwae379.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjpc\/article-pdf\/33\/1\/30\/60950094\/zwae379.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T12:17:31Z","timestamp":1767701851000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjpc\/article\/33\/1\/30\/7909733"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,27]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,11,27]]},"published-print":{"date-parts":[[2026,1,6]]}},"URL":"https:\/\/doi.org\/10.1093\/eurjpc\/zwae379","relation":{},"ISSN":["2047-4873","2047-4881"],"issn-type":[{"value":"2047-4873","type":"print"},{"value":"2047-4881","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1]]},"published":{"date-parts":[[2024,11,27]]}}}